Keynote review: Structural biology and drug discovery

Drug Discovery Today

Volumn 10, Issue 13, 2005, Pages 895-907

  Congreve, Miles ^a   Murray, Christopher W ^a   Blundell, Tom L ^{b,c,d,e,f,g,h,i}  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Department of Biochemistry ^*  (United Kingdom)

^d Academia Europaea   (United Kingdom)

^e Academy of Medical Sciences   (United Kingdom)

^f LINACRE COLLEGE   (United Kingdom)

^g UNIVERSITY OF LONDON   (United Kingdom)

^h Royal Commission on Environmental Pollution   (United Kingdom)

ⁱ Astex Technology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUVIRAN; AMPRENAVIR; BCR ABL PROTEIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CAPTOPRIL; DORZOLAMIDE; ERLOTINIB; GYRASE INHIBITOR; IMATINIB; INDAZOLE DERIVATIVE; LAPATINIB; LOPINAVIR; NELFINAVIR; NOVOBIOCIN; OSELTAMIVIR; PHOSPHOTRANSFERASE INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; QUINAZOLINONE DERIVATIVE; SIALIDASE; XIMELAGATRAN; ZANAMIVIR;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; BINDING SITE; BIOTECHNOLOGY; COMPUTER MODEL; CRYSTAL STRUCTURE; DRUG APPROVAL; DRUG BINDING SITE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME STRUCTURE; HUMAN; LIGAND BINDING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN STRUCTURE; REVIEW; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; STRUCTURAL GENOMICS; STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING; X RAY ANALYSIS; METHODOLOGY; PHARMACEUTICS; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

DRUG DESIGN; HUMANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 21544474149     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03484-7     Document Type: Review

References (128)

1. Beddell C.R. Compounds designed to fit a site of known structure in human haemoglobin Br. J. Pharmacol. 57 1976 201 209
2. Goodford P.J. The interaction of human haemoglobin with allosteric effectors as a model for drug-receptor interactions Br. J. Pharmacol. 68 1980 741 748
3. Blundell T.L. The structure, chemistry and biological activity of insulin Adv. Protein Chem. 26 1972 279 402
4. Davie E.W. The coagulation cascade: initiation, maintenance and regulation Biochemistry 30 1991 10363 10370
5. Blundell T.L. Structure-based drug design Nature 384 1996 23 26
6. Sibanda B.L. Three-dimensional structure, specificity and catalytic mechanism of renin Nature 304 1983 273 275
7. Campbell S.F. Science, art and drug discovery: a personal perspective Clin. Sci. 99 2000 255 260
8. Miller M. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 ANG. resolution Science 246 1989 1149 1152
9. Lapatto R. X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes Nature 342 1989 299 302
10. Varghese J.N. Development of neuraminidase inhibitors as anti-influenza virus drugs Drug Dev. Res. 46 1999 176 196
11. Hardy L.W., Malikayil A. The impact of structure-guided drug design on clinical agents Curr. Drug Discov 2003 15 20 December
12. Lombardino J.G., Lowe J.A. A guide to drug discovery: the role of the medicinal chemist in drug discovery - then and now Nat. Rev. Drug Discov. 3 2004 853 862
13. Wong S., Witte O.N. The BCR-ABL story: bench to bedside and back Annu. Rev. Immunol. 22 2004 247 306
14. Blundell T. 18th Sir Hans Krebs Lecture. Knowledge-based protein modelling and design Eur. J. Biochem. 172 1988 513 520
15. Pearl L.H., Taylor W.R. A structural model for the retroviral proteases Nature 329 1987 351 354
16. Bowie J.U. A method to identify protein sequences that fold into a known three-dimensional structure Science 253 1991 164 170
17. Rice D.W., Eisenberg D. A 3D-1D substitution matrix for protein fold recognition that includes predicted secondary structure of the sequence J. Mol. Biol. 267 1997 1026 1038
18. Overington J. Tertiary structural constraints on protein evolutionary diversity: templates, key residues and structure prediction Proc. Biol. Sci. 241 1990 132 145
19. Johnson M.S. Alignment and searching for common protein folds using a data bank of structural templates J. Mol. Biol. 231 1993 735 752
20. Shi J. Fugue: sequence-structure homology recognition using environment-specific substitution tables and structure-dependent gap penalties J. Mol. Biol. 310 2001 243 257
21. Jones D.T. A new approach to protein fold recognition Nature 358 1992 86 89
22. Lindahl E., Elofsson A. Identification of related proteins on family, superfamily and fold level J. Mol. Biol. 295 2000 613 625
23. Jones D.T. GenTHREADER: an efficient and reliable protein fold recognition method for genomic sequences J. Mol. Biol. 287 1999 797 815
24. Sutcliffe M.J. Knowledge-based modelling of homologous proteins, part I: three-dimensional frameworks derived from the simultaneous superposition of multiple structures Protein Eng. 1 1987 377 384
25. Guex N. Protein modelling for all Trends Biochem. Sci. 24 1999 364 367
26. Sali A., Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints J. Mol. Biol. 234 1993 779 815
27. Venclovas C. Assessment of progress over the CASP experiments Proteins 53 Suppl. 6 2003 585 595
28. Diller D.J., Li R. Kinases, homology models, and high-throughput docking J. Med. Chem. 46 2003 4638 4647
29. Chuaqui C. Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening J. Med. Chem. 48 2005 121 133
30. Heinemann U. Facilities and methods for the high-throughput crystal structural analysis of human proteins Acc. Chem. Res. 36 2003 157 163
31. Service R.F. Structural genomics. Tapping DNA for structures produces a trickle Science 298 2002 948 950
32. Rupp B. High-throughput crystallography at an affordable cost: the TB Structural Genomics consortium crystallization facility Acc. Chem. Res. 36 2003 173 181
33. Lesley S.A. Structural genomics of the Thermotoga maritima proteome implemented in a high-throughput structure determination pipeline Proc. Natl. Acad. Sci. U. S. A. 99 2002 11664 11669
34. Chambers S.P. High-throughput protein expression for the post-genomic era Drug Discov. Today 7 2002 759 765
35. Endo Y., Sawasaki T. High-throughput, genome-scale protein production method based on the wheat germ cell-free expression system Biotechnol. Adv. 21 2003 695 713
36. Lanio T. High-throughput purification of polyHis-tagged recombinant fusion proteins Methods Mol. Biol. 205 2003 199 203
37. Scheich C. An automated method for high-throughput protein purification applied to a comparison of His-tag and GST-tag affinity chromatography BMC Biotechnol. 3 2003 12 17
38. Hui R., Edwards A. High-throughput protein crystallization J. Struct. Biol. 142 2003 154 161
39. Chayen N.E., Saridakis E. Protein crystallization for genomics: towards high-throughput optimization techniques Acta Crystallogr. D Biol. Crystallogr. 58 2002 921 927
40. Stewart L. High-throughput crystallization and structure determination in drug discovery Drug Discov. Today 7 2002 187 196
41. Bodenstaff E.R. The prospects of protein nanocrystallography Acta Crystallogr. D Biol. Crystallogr. 58 2002 1901 1906
42. Muchmore S.W. Automated crystal mounting and data collection for protein crystallography Structure Fold. Des. 8 2000 R243 R246
43. Sharff A. High-throughput crystallography on an in-house source using ACTOR The Rigaku Journal 19 2003 5 10
44. Sheldrick G.M. Patterson superposition and ab initio phasing Methods Enzymol. 276 1997 628 641
45. Weeks C.M., Miller R. Optimizing shake and bake for proteins Acta Crystallogr. D Biol. Crystallogr. 55 1999 492 500
46. Lamzin V.S., Perrakis A. Automated protein model building combined with iterative structure refinement Nat. Struct. Biol. 7 2000 978 981
47. DePristo M.A. Heterogeneity and inaccuracy in protein structures solved by X-ray crystallography Structure 12 2004 831 838
48. Williams P.A. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity Mol. Cell 5 2000 121 131
49. Williams P.A. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone Science 305 2004 683 686
50. Yano J.K. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-ANG resolution J. Biol. Chem. 279 2004 38091 38094
51. Hofmann K. The PROSITE database, its status in 1999 Nucleic Acids Res. 27 1999 215 219
52. Kasuya A., Thornton J.M. Three-dimensional structure analysis of PROSITE patterns J. Mol. Biol. 286 1999 1673 1691
53. Herzberg O., Moult J. Analysis of the steric strain in the polypeptide backbone of protein molecules Proteins 11 1991 223 229
54. Heringa J., Argos P. Strain in protein structures as viewed through nonrotameric side chains: II. Effects upon ligand binding Proteins 37 1999 44 55
55. Laskowski R. Protein clefts in molecular recognition and function Protein Sci. 5 1996 2438 2452
56. Zvelebil M.J. Prediction of protein secondary structure and active sites using the alignment of homologous sequences J. Mol. Biol. 195 1987 957 961
57. McPhalen C.A. Domain closure in mitochondrial aspartate aminotransferase J. Mol. Biol. 227 1992 197 223
58. Irving J.A. Protein structural alignments and functional genomics Proteins 42 2001 378 382
59. Lichtarge O., Sowa M.A. Evolutionary predictions of binding surfaces and interactions Curr. Opin. Struct. Biol. 12 2002 21 27
60. Chelliah V. Distinguishing structural and functional restraints in evolution in order to identify interaction sites J. Mol. Biol. 342 2004 1487 1504
61. Seneci P., Miertus S. Combinatorial chemistry and high-throughput screening in drug discovery: different strategies and formats Mol. Divers. 5 2000 75 89
62. Bailey N. Solution-phase combinatorial chemistry in lead discovery Chimia 51 1997 832 837
63. Dolle R.E. Comprehensive survey of combinatorial library synthesis: 2003 J. Comb. Chem. 6 2004 623 679
64. Spencer R.W. High-throughput screening of historic collections: observations on file size, biological targets, and file diversity Biotechnol. Bioeng. 61 1998 61 67
65. Hopkins A.L., Groom C.R. Opinion: the druggable genome Nat. Rev. Drug Discov. 1 2002 727 730
66. Taylor R.D. A review of protein-small molecule docking methods J. Comput. Aided Mol. Des. 16 2002 151 166
67. Nissink J.W.M. A new test set for validating predictions of protein-ligand interaction Proteins 49 2002 457 471
68. Friesner R.A. Glide: a new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy J. Med. Chem. 47 2004 1739 1749
69. Kitchen D.B. Docking and scoring in virtual screening for drug discovery: methods and applications Nat. Rev. Drug Discov. 3 2004 935 949
70. Shoichet B.K. Lead discovery using molecular docking Curr. Opin. Chem. Biol. 6 2002 439 446
71. Bajorath J. Integration of virtual and high-throughput screening Nat. Rev. Drug Discov. 1 2002 882 894
72. Lyne P.D. Structure-based virtual screening: an overview Drug Discov. Today 7 2002 1047 1052
73. Jain A.N. Virtual screening in lead discovery and optimization Curr. Opin. Drug Discov. Devel. 7 2004 396 403
74. Abagyan R., Totrov M. High-throughput docking for lead generation Curr. Opin. Chem. Biol. 5 2001 375 382
75. Boehm H-J. Novel inhibitors of DNA gyrase: 3D structure-based biased needle screening, hit validation by biophysical methods, and 3D-guided optimization. A promising alternative to random screening J. Med. Chem. 43 2000 2664 2674
76. Vangrevelinghe E. Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking J. Med. Chem. 46 2003 2656 2662
77. Ewing T.J. Dock 4.0: search strategies for automated molecular docking of flexible molecule databases J. Comput. Aided Mol. Des. 15 2001 411 428
78. Knegtel R.M.A. Molecular docking to ensembles of protein structures J. Mol. Biol. 266 1997 424 440
79. Gohlke H., Klebe G. DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein J. Med. Chem. 45 2002 4153 4170
80. Wu G., Vieth M. SDOCKER: a method utilizing existing X-ray structures to improve docking accuracy J. Med. Chem. 47 2004 3142 3148
81. Hindle S.A. Flexible docking under pharmacophore type constraints J. Comput. Aided Mol. Des. 16 2002 129 149
82. Ferrari A.M. Soft docking and multiple receptor conformations in virtual screening J. Med. Chem. 47 2004 5076 5084
83. Kovacs J.A. Predictions of protein flexibility: first-order measures Proteins 56 2004 661 668
84. Claussen H. FlexE: efficient molecular docking considering protein structure variations J. Mol. Biol. 308 2001 377 395
85. Rarey M. The particle concept: placing discrete water molecules during protein-ligand docking predictions Proteins 34 1999 17 28
86. Cohen N.C., Tschinke N. Generation of new-lead structures in computer-aided drug design Prog. Drug Res. 45 1995 205 243
87. Murcko M.A. Recent advances in ligand design methods Rev. Comput. Chem. 11 1997 1 66
88. Clark D.E. Current issues in de novo molecular design Rev. Comput. Chem. 11 1997 67 125
89. Honma T. Recent advances in de novo design strategy for practical lead identification Med. Res. Rev. 23 2003 606 632
90. Dean P.M. De novo drug design: integration of structure-based and ligand-based methods Curr. Opin. Drug Discov. Devel. 7 2004 347 353
91. Stahl M. A validation study on the practical use of automated de novo design J. Comput. Aided Mol. Des. 16 2002 459 478
92. Wyss P.C. Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening J. Med. Chem. 46 2003 2304 2312
93. Doman T.N. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1b J. Med. Chem. 45 2002 2213 2221
94. Bohm H-J., Stahl M. Structure-based library design: molecular modeling merges with combinatorial chemistry Curr. Opin. Chem. Biol. 4 2000 283 286
95. Laird E.R. Structure-based generation of viable leads from small combinatorial libraries Curr. Opin. Drug Discov. Devel. 7 2004 354 359
96. Liebeschuetz J.W. PROSELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors J. Med. Chem. 45 2002 1221 1232
97. Adams C. Mapping the kinase domain of janus kinase 3 Bioorg. Med. Chem. Lett. 13 2003 3105 3110
98. Hopkins A.L. Ligand efficiency: a useful metric for lead selection Drug Discov. Today 9 2004 430 431
99. Shuker S.B. Discovering high-affinity ligands for proteins: SAR by NMR Science 274 1996 1531 1534
100. Fejzo J. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery Chem. Biol. 6 1999 755 769
101. Muchmore S.W., Hajduk P.J. Crystallography, NMR and virtual screening: integrated tools for drug discovery Curr. Opin. Drug Discov. Devel. 6 2003 544 549
102. Moore J. Leveraging structural approaches: applications of NMR screening and X-ray crystallography for inhibitor design J. Synchrotron Radiat. 11 2004 97 110
103. Verlinde C.L.M.J. Antitrypanosomiasis drug development based on structures of glycolytic enzymes Veerapandian P. In Structure-Based Drug Design 1997 Marcel Dekker 365 394
104. Nienaber V.L. Discovering novel ligands for macromolecules using X-ray crystallographic screening Nat. Biotechnol. 18 2000 1105 1108
105. Lesuisse D. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: Application to the discovery of nanomolar inhibitors of Src SH2 J. Med. Chem. 45 2002 2379 2387
106. Hirth K-P., Milburn M.V. Methods for the design of molecular scaffolds and ligands US Patent Application Publication No. US2004/0171062 2004
107. Blundell T.L. High-Throughput X-ray Crystallography for Drug Discovery Flower D. In Drug Design, Cutting Edge Approaches 2002 Royal Society Chemistry 53 59
108. Carr R., Jhoti H. Structure-based screening of low affinity compounds Drug Discov. Today 7 2003 522 527
109. Hartshorn M.J. Fragment-based lead discovery using X-ray crystallography J. Med. Chem. 48 2005 403 413
110. Gill A.L. Identification of novel p38a MAP kinase inhibitors using fragment-based lead generation J. Med. Chem. 48 2005 414 426
111. Rees D.C. Fragment-based lead discovery Nat. Rev. Drug Discov. 3 2004 660 672
112. Erlanson D.A. Fragment-based drug discovery J. Med. Chem. 47 2004 3463 3482
113. Parang K., Sun G. Design strategies for protein kinase inhibitors Curr. Opin. Drug Discov. Devel. 7 2004 617 629
114. Gill A. New lead generation strategies for protein kinase inhibitors - fragment-based screening approaches Mini Rev. Med. Chem. 4 2004 301 311
115. Fabian M.A. A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 23 2005 329 336
116. Mol C.D. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors Curr. Opin. Drug Discov. Devel. 7 2004 639 648
117. Wood E.R. A unique structure for the epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res. 64 2004 6652 6659
118. Cushman D.W. Design of potent inhibitors of ACE Biochemistry 16 1977 5484 5491
119. Baldwin J.J. Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma J. Med. Chem. 32 1989 2510 2513
120. Kaldor S.W. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease J. Med. Chem. 40 1997 3979 3985
121. Kim E.E. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme J. Am. Chem. Soc. 117 1995 1181 1182
122. Sham H.L. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease Antimicrob. Agents Chemother 42 1998 3218 3224
123. von Itzstein M. Rational design of potent sialidase-based inhibitors of influenza virus replication Nature 363 1993 418 423
124. Kim C.U. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors J. Med. Chem. 41 1998 2451 2460
125. Zimmermann J. (Phenylamino)pyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors Bioorg. Med. Chem. Lett. 6 1996 1221 1226
126. Zimmermann J. Potent and selective inhibitors of the ABL-kinase: phenylaminopyrimidine (PAP) derivatives Bioorg. Med. Chem. Lett. 7 1997 187 192
127. Pollack V.A. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice J. Pharmacol. Exp. Ther. 291 1999 739 748
128. Gustafsson D. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects Thromb. Res. 101 2001 171 181